Although pharmacovigilance studies have found increased reporting rates for thyroid cancer with GLP1 receptor agonists,2, 3 disproportionality analyses are designed to detect potential safety signals but are not intended to make causal conclusions. The gene discussed is GLP1R; the disease is thyroid cancer.